title: Thioredoxin reductase inactivation as a pivotal mechanism of ifosfamide in cancer therapy.
abstract: Thioredoxin reductase reduces thioredoxin, thereby contributing to multiple cellular events related to carcinogenesis including cell proliferation, apoptosis, and cell signaling. This selenium-containing oxidoreductase is over-expressed in many malignant cells and has been proposed as a target for cancer therapy. Ifosfamide is an oxazaphosphorine alkylating agent with a broad spectrum of antineoplastic activity. The purpose of this study is to test the hypothesis that anticancer efficacy of ifosfamide may rely on its ability to inhibit thioredoxin reductase in tumor. To inspect the consequence of thioredoxin reductase inhibition by ifosfamide on tumor cell proliferation, mice bearing hepatoma 22 (H22) cells in ascites were injected with 350 mg/kg ifosfamide. Thioredoxin reductase activity was maximally inhibited by half at 6 h, and a subsequent pronounced cellular proliferation inhibition due to cell cycle arrest in G(1) phase was found. Moreover, at 6 h, except thioredoxin reductase inhibition, ifosfamide did not affect cell cycle or other measured antioxidant enzymes activity in the tumor cells. Intriguingly, when these cells were injected into healthy mice, they totally lost the capacity of causing either ascitic or solid tumors. Thioredoxin reductase inhibition could also be found in solid H22 tumor by 62%, bladder by 74% and kidney by 37% at 6 h. Overall, these observations provide direct evidence that inhibition of thioredoxin reductase activity in malignant cells by ifosfamide is highly associated with its anticancer effect and the mechanism of ifosfamide systemic toxicity may be related to multi-organ inhibition of thioredoxin reductase activity.
authors.affiliation: University of Science and Technology of China, Hefei 230052, Anhui, PR China.
authors.forename: Xufang
authors.initials: X
authors.lastname: Wang
authors.forename: Jinsong
authors.initials: J
authors.lastname: Zhang
authors.forename: Tongwen
authors.initials: T
authors.lastname: Xu
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D001201:Ascites / Q000188:drug therapy / Q000473:pathology; D002453:Cell Cycle / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D016193:G1 Phase / Q000187:drug effects; D007069:Ifosfamide / Q000494:pharmacology*; D007668:Kidney / Q000187:drug effects / Q000201:enzymology; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy*; D008297:Male; D051379:Mice; D013880:Thioredoxin-Disulfide Reductase / Q000037:antagonists & inhibitors*; D001743:Urinary Bladder / Q000187:drug effects / Q000201:enzymology
chemical_list: D018906:Antineoplastic Agents, Alkylating; D013880:Thioredoxin-Disulfide Reductase; D007069:Ifosfamide